3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
5
Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid Neoplasms
1
Ovarian Cancer Metastatic
1
Neoplasms
1
Multiple Myeloma
1
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
1
Metastatic Bladder Urothelial Carcinoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
aldesleukin
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn